Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) insider Benjamin T. Dake sold 3,432 shares of the firm's stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $28.01, for a total value of $96,130.32. Following the completion of the transaction, the insider now directly owns 1,291 shares in the company, valued at $36,160.91. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Aerovate Therapeutics Trading Up 11.1 %
Shares of AVTE stock opened at $28.50 on Thursday. The stock has a 50 day moving average of $21.99 and a two-hundred day moving average of $17.62. Aerovate Therapeutics, Inc. has a 12 month low of $9.41 and a 12 month high of $29.36.
Institutional Trading of Aerovate Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVTE. Alps Advisors Inc. lifted its holdings in Aerovate Therapeutics by 11.3% during the 3rd quarter. Alps Advisors Inc. now owns 20,395 shares of the company's stock valued at $277,000 after purchasing an additional 2,075 shares during the last quarter. Swiss National Bank raised its position in shares of Aerovate Therapeutics by 30.9% in the 3rd quarter. Swiss National Bank now owns 21,201 shares of the company's stock valued at $288,000 after acquiring an additional 5,000 shares during the period. Silverarc Capital Management LLC bought a new stake in shares of Aerovate Therapeutics in the 3rd quarter valued at $1,357,000. Driehaus Capital Management LLC bought a new position in shares of Aerovate Therapeutics during the 2nd quarter valued at about $20,479,000. Finally, HighVista Strategies LLC lifted its stake in Aerovate Therapeutics by 164.0% in the second quarter. HighVista Strategies LLC now owns 41,803 shares of the company's stock valued at $717,000 after buying an additional 25,970 shares in the last quarter.
Wall Street Analyst Weigh In
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders | Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
A number of research firms have weighed in on AVTE. Wells Fargo & Company began coverage on shares of Aerovate Therapeutics in a research report on Friday, December 8th. They set an "equal weight" rating and a $35.00 target price for the company. Jefferies Financial Group started coverage on Aerovate Therapeutics in a research report on Monday. They issued a "buy" rating and a $65.00 price target on the stock.
Read Our Latest Stock Analysis on AVTE
About Aerovate Therapeutics
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
